Incorrect injection technique is a primary cause of posterior vitreous detachment; our findings were consistent with the previous report of a low rate (0 to 0.67%) of RD and RT following anti-VEGF IVI.63 In a meta-analysis of 8 RCTs evaluating the systemic safety of intravitreal anti-VEGF agents for treatment of retinal vein occlusion, anti-VEGF drugs did not increase the risks of cardiovascular events compared with placebo/retinal photocoagulation.10 The gene discussed is VEGFA; the disease is retinal vein occlusion.